These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

94 related items for PubMed ID: 7858530

  • 61.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 62.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 63.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 64.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 65.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 66.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 67.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 68. Heat shock protein vaccination and directed IL-2 therapy amplify tumor immunity rapidly following bone marrow transplantation in mice.
    Newman RG, Dee MJ, Malek TR, Podack ER, Levy RB.
    Blood; 2014 May 08; 123(19):3045-55. PubMed ID: 24687086
    [Abstract] [Full Text] [Related]

  • 69. Cell biology and possible therapeutic applications of anti-CD3-activated killer-T cells (review).
    Hoskin DW, Williams B, Fitzpatrick L, Makrigiannis AP.
    Int J Mol Med; 1998 May 08; 1(5):893-902. PubMed ID: 9852313
    [Abstract] [Full Text] [Related]

  • 70. [Prevention of cancer recurrence by infusion of activated autologous lymphocytes].
    Sekine T, Takayama T, Konomi Y, Kakizoe T.
    Hum Cell; 1994 Sep 08; 7(3):121-4. PubMed ID: 7873494
    [Abstract] [Full Text] [Related]

  • 71. Augmentation of the therapeutic efficacy of adoptive tumor immunotherapy by in vivo administration of slowly released recombinant interleukin 2.
    Nishimura T, Togashi Y, Goto M, Yagi H, Uchiyama Y, Hashimoto Y.
    Cancer Immunol Immunother; 1986 Sep 08; 21(1):12-8. PubMed ID: 3484674
    [Abstract] [Full Text] [Related]

  • 72. Cyclophosphamide plus tumor necrosis factor-alpha chemoimmunotherapy cured mice: life-long immunity and rejection of re-implanted primary lymphoma.
    Ehrke MJ, Verstovsek S, Krawczyk CM, Ujházy P, Zaleskis G, Maccubbin DL, Mihich E.
    Int J Cancer; 1995 Nov 03; 63(3):463-71. PubMed ID: 7591249
    [Abstract] [Full Text] [Related]

  • 73. The effect of continuous infusion IL-1 alpha on carboplatin-induced thrombocytopenia and anti-tumor activity in RIF-1 tumor bearing mice.
    Yu W, Chang M, Vlock D, Furmanski P, Johnson C.
    Oncol Rep; 1997 Nov 03; 4(1):43-8. PubMed ID: 21590009
    [Abstract] [Full Text] [Related]

  • 74.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 75.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 76.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 77.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 78.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 79. A translational bridge to cancer immunotherapy: exploiting costimulation and target antigens for active and passive T cell immunotherapy.
    Vonderheide RH, June CH.
    Immunol Res; 2003 Nov 03; 27(2-3):341-56. PubMed ID: 12857980
    [Abstract] [Full Text] [Related]

  • 80. Induction of anti-tumour lymphocytes in cancer patients after brief exposure to supernatants from cultures of anti-CD3-stimulated allogeneic lymphocytes.
    Baxevanis CN, Tsiatas ML, Cacoullos NT, Spanakos G, Liacos C, Missitzis I, Papadhimitriou SI, Papamichail M.
    Br J Cancer; 1997 Nov 03; 76(8):1072-80. PubMed ID: 9376269
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 5.